The biotechnology sector has broken out of its multiyear bear market. As macroeconomic headwinds moderate and regulatory environments stabilize, biotech ETFs are surging. Furthermore, the industry is undergoing structural transformation amid a period of M&A activity.
Key Takeaways
- The State Street SPDR S&P Biotech ETF (XBI) gained 17.9% in the first half of 2026, driven by a powerful wave of small-cap consolidation.
- Anthropic CEO Dario Amodei notes that advanced generative AI models can compress decades of biological legwork into short experimental cycles.
- Large pharmaceutical companies face a $280 billion patent cliff by 2028, accelerating the necessity for strategic corporate acquisitions.
AI Innovation and Corporate Consolidation Driving Biotech ETFs
Advancements in computational tools are shifting the biotech investment landscape. AI foundation models are predicting complex biological designs and protein structures, reducing early-stage discovery costs. This shifts downstream efficiency dramatically for clinical-stage firms.
At the same time, large pharmaceutical corporations are aggressively acquiring mid- and small-cap clinical pipelines. Expected interest rate cuts alongside clearer drug pricing regulations have lowered the cost of capital for buyers. Recent M&A deals — such as Novartis acquiring Avidity Biosciences and Merck purchasing Terns Pharmaceuticals — underscore this targeted industry consolidation.
Selecting the Right Vehicle for Exposure to Biotech ETFs
For investors looking to add exposure to biotech ETFs, it’s important to look under the hood as index methodology changes exposure dramatically.
State Street SPDR S&P Biotech ETF (XBI )
The State Street SPDR S&P Biotech ETF (XBI ) is the largest ETF in the segment with $9 billion in assets. The fund tracks an equal-weight indexing strategy offers unconcentrated industry exposure across large, mid- and small-cap stocks. XBI has delivered a 77.9% return over a one-year period ending June 22.
iShares Biotechnology ETF BB
Meanwhile, the $8.1 billion iShares Biotechnology ETF BB favors established mega-cap and large-cap biotech companies, delivering a 41.4% return over the past year.
VanEck Biotech ETF (BBH )
The VanEck Biotech ETF (BBH ) is heavily concentrated in large companies like Amgen (AMGN) and Gilead Sciences (GILD). BBH leans directly into dominant commercialized firms driving AI integration. It has posted a return of 24.8% in the past one-year period.
Invesco Biotechnology & Genome ETF (PBE )
The Invesco Biotechnology & Genome ETF (PBE ) employs a multi-factor approach. PBE focuses on enterprises primarily engaged in the R&D, production, and commercialization of biotech offerings, as well as firms that gain a competitive edge through technological breakthroughs in genetic engineering and biological research. It captured a 35.9% return over the same period.
ALPS Medical Breakthroughs ETF (SBIO )
Finally, the ALPS Medical Breakthroughs ETF (SBIO ) explicitly requires constituents to maintain clinical phase II or phase III trials. SBIO achieved a sector-leading 95.5% return in the past year. Notably, SBIO continues to outpace all its major peers across the one-, three-, five-, and 10-year investment horizons.
For more news, information, and analysis, visit the Thematic Investing Content Hub.
VettaFi LLC (“VettaFi”) is the index provider for SBIO, for which it receives an index licensing fee. However, SBIO is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of SBIO.
